(Q43137255)

English

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study

scientific article published in April 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 November 2017

Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study (English)

1 reference

Europe PubMed Central

14 November 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Joachim Stangier

1

1 reference

Europe PubMed Central

14 November 2017

Karin Rathgen

2

1 reference

Europe PubMed Central

14 November 2017

Hildegard Stähle

3

1 reference

Europe PubMed Central

14 November 2017

Dago Mazur

4

1 reference

Europe PubMed Central

14 November 2017

publication date

1 April 2010

1 reference

Europe PubMed Central

14 November 2017

Clinical Pharmacokinetics

1 reference

Europe PubMed Central

14 November 2017

49

1 reference

Europe PubMed Central

14 November 2017

259-268

1 reference

Europe PubMed Central

14 November 2017

4

1 reference

Europe PubMed Central

14 November 2017

https://scigraph.springernature.com/pub.10.2165/11318170-000000000-00000

0 references

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.2165%2F11318170-000000000-00000

21 January 2018

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug binding in plasma. A summary of recent trends in the study of drug and hormone binding

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

1 reference

https://pubmed.ncbi.nlm.nih.gov/20214409

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11318170-000000000-00000

1 reference

Europe PubMed Central

14 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43137255&oldid=1981530489"